AbbVie account plan
Biopharmaceutical medicine creation
At a glance
AbbVie is a US biopharmaceutical company in immunology, neuroscience, oncology and aesthetics: $61.2 billion 2025 net revenues, about 57,000 employees.
AbbVie is a research-based biopharmaceutical company, spun off from Abbott Laboratories on January 1, 2013, with leadership positions in immunology, neuroscience, oncology and aesthetics, plus eye care and other products. It markets mainly to prescribers, sells through wholesalers, specialty pharmacies, health care facilities and government agencies, and reports a single global business segment. FY2025 net revenues were $61.2 billion, up 8.6%, with the United States at $46,603 million; operating earnings were $15.1 billion and operating cash flow $19.0 billion. It employed approximately 57,000 people in over 70 countries at December 31, 2025. Robert A. Michael is Chairman and CEO.
Business units
Immunology
about $30.4 billion FY2025, roughly 50% of net revenuesSkyrizi ($17,562 million, +49.9%) and Rinvoq ($8,304 million, +39.1%) for psoriasis, inflammatory bowel disease, arthritis and atopic dermatitis made up approximately 42% of net revenues, while Humira fell 49.5% under biosimilar competition. Both main brands grew about 24% in Q2 2026, and 2026 guidance is $34.5 billion.
Neuroscience
about $10.8 billion FY2025, roughly 18% of net revenuesVraylar for schizophrenia and bipolar disorder, Botox Therapeutic, the migraine orals Ubrelvy and Qulipta, and Parkinson's treatments Vyalev and Duodopa. Revenues grew approximately 20% in Q2 2026, and management targets Parkinson's and migraine franchises each above $5 billion of peak sales.
Oncology
about $6.7 billion FY2025, roughly 11% of net revenuesImbruvica, Venclexta, Elahere, Epkinly and newer antibody-drug conjugates such as Emrelis and Decnupaz. Imbruvica fell 29.4% in Q2 2026 on IRA pricing and competition, pulling oncology revenues down 2.4%.
Aesthetics
about $4.9 billion FY2025, roughly 8% of net revenuesBotox Cosmetic, Juvederm fillers, CoolSculpting, Natrelle implants and SkinMedica, also sold directly to physicians. Botox Cosmetic fell 4.3% and Juvederm 15.6% in 2025 on weaker consumer demand; the short-acting toxin trenibotulinumtoxinE was approved in Europe as Boey after an FDA Complete Response Letter.
Eye care
about $2.1 billion FY2025, roughly 3% of net revenuesOzurdex, Lumigan/Ganfort, Alphagan/Combigan and other eye care products including Refresh, Xen, Durysta and Restasis.
Other key products
Creon pancreatic enzymes ($1,512 million in 2025), Mavyret for hepatitis C ($1,317 million) and Linzess ($907 million), plus the antibiotic Emblaveo approved in the U.S. in February 2025.
Strategic priorities
- Grow Skyrizi and Rinvoq into the 2030s
- 2026 guidance is $21.7 billion for Skyrizi and $10.1 billion for Rinvoq; new Rinvoq indications in vitiligo and alopecia areata are expected to approach $2 billion of peak sales, and Skyrizi regulatory data protection runs to 2031.
- Build neuroscience into a second engine
- Neuroscience guidance is $12.7 billion for 2026, with Parkinson's (Vyalev, Duodopa, tavapadon) and migraine each targeted above $5 billion of peak sales.
- High single-digit growth through 2029
- Management targets high single-digit revenue growth through 2029, with no significant losses of exclusivity until the next decade; 2026 revenue guidance was raised to approximately $67.6 billion.
- External innovation and obesity
- Over $8 billion invested in external innovation in two years across more than 30 deals, in immunology, neuroscience, oncology and obesity, as a new source of growth; the pipeline holds approximately 90 programs, approximately 60 in mid- and late-stage development.
- U.S. investment pledge
- The January 2026 agreement with the U.S. government commits low Medicaid prices, direct-to-patient offerings and $100 billion of U.S. R&D and capital investment over the next decade, in exchange for a three-year exemption from tariffs and future price mandates.
Latest results
In Q2 2026, net revenues were $16,990 million, up 10.2% (9.5% at constant currency), and first-half revenues $32.0 billion, up 11.2%. Q2 net earnings attributable to AbbVie were $3,613 million against $938 million a year earlier, and the gross margin rose to 75% of net revenues on lower amortisation. Skyrizi reached $5,505 million (+24.4%) and Rinvoq $2,525 million (+24.5%), while Imbruvica fell 29.4%. Full-year 2026 revenue guidance was raised to approximately $67.6 billion, with adjusted EPS guidance of $13.87 to $14.07 including $0.14 of Apogee dilution; Q3 guidance was net revenues of approximately $17.2 billion.
Investments and deals
- Apogee Therapeutics acquisition
- Definitive agreement in June 2026 to acquire Apogee for $135.11 per share, about $10.9 billion, adding biologics for atopic dermatitis, asthma and other inflammatory conditions; backed by a $10.0 billion 364-day term loan.
- 2025 business development
- Acquired IPR&D and milestones of $5,016 million in 2025, including Capstan's in vivo CAR-T, Gilgamesh's bretisilocin, Ichnos Glenmark's ISB-2001, Gubra's amylin analog for obesity and ADARx's siRNA options.
- RemeGen PD-1/VEGF license
- License of RemeGen's RC148 bispecific for all markets excluding China, with $650 million upfront and up to $5.0 billion of milestones.
- U.S. manufacturing expansion
- A new API plant in Illinois, two new Illinois facilities for neuroscience and obesity medicines, a manufacturing campus in North Carolina, biologics and R&D expansion in Massachusetts, and an Arizona device plant acquisition closed in July 2026.
Challenges and risks
- Humira biosimilar erosion
- Humira fell 49.5% to $4,540 million in 2025, after nearly $16 billion of U.S. erosion since its loss of exclusivity, and access will decrease further in 2026.
- U.S. government price setting
- IRA government-set prices apply to Imbruvica from 2026, Vraylar and Linzess from 2027 and Botox from 2028, and low single-digit pricing headwinds are expected for Skyrizi and Rinvoq.
- Weak aesthetics demand
- Aesthetics category growth is expected to remain challenged in 2026 on economic headwinds, and the FDA issued a Complete Response Letter for trenibotulinumtoxinE on manufacturing questions.
- Concentration and impairment risk
- Skyrizi and Rinvoq made up approximately 42% of 2025 net revenues, and $52.6 billion of intangibles plus $35.6 billion of goodwill are subject to impairment.
- Manufacturing and supply complexity
- The 10-K names biologics manufacturing complexity, single-source suppliers and dependence on three U.S. wholesalers as risks.
What leadership says
“we are well-positioned to deliver high single-digit revenue growth through 2029.”
“we have plenty of capacity to invest in both internal and external innovation”
“We have ample financial capacity for more business development.”
“regulatory data protection for SKYRIZI does not expire until 2031”
Where a supplier can help
- U.S. manufacturing build-out
- The $100 billion U.S. investment pledge and new plants in Illinois, North Carolina, Massachusetts and Arizona create demand for engineering, construction, equipment validation and manufacturing systems suppliers.
- Launch support for new indications
- Launches such as Rinvoq in vitiligo and alopecia areata, tavapadon in Parkinson's and Skyrizi subcutaneous induction in Crohn's fit commercial-execution partners: medical education, field force analytics and patient support.
- Clinical development capacity
- With approximately 60 programs in mid- and late-stage development and Phase 3 starts in colorectal and small cell lung cancer, CROs, trial technology and data vendors can support the pipeline priority.
- Direct-to-patient and market access
- The government agreement's direct-to-patient offerings and the IRA price-setting challenge make pharmacy, hub services and market access analytics providers relevant.
- Injector training for aesthetics
- The trenibotulinumtoxinE launch requires training 12,000 core injectors, an opening for training, practice-management and consumer marketing partners as aesthetics demand stays weak.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like AbbVie?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 10-K for fiscal year 2025
- AbbVie is a research-based biopharmaceutical group (spun off from Abbott on January 1, 2013) with leadership positions in immunology, neuroscience, oncology and aesthetics; it reports a single global business segment and employed approximately 57,000 people in over 70 countries at December 31, 2025.
- FY2025 worldwide net revenues of $61.2 billion, up 8.6% reported (8.5% at constant currency): United States $46,603 million (+8.3%), International $14,557 million (+9.4%). Operating earnings $15.1 billion, diluted EPS $2.36, operating cash flow $19.0 billion.
- Concentration: Skyrizi ($17,562 million, +49.9%) and Rinvoq ($8,304 million, +39.1%) together accounted for approximately 42% of net revenues; Humira fell 49.5% to $4,540 million under biosimilar competition.
- Growth brands outside immunology: Vraylar $3,621 million (+10.8%), Botox Therapeutic $3,769 million (+14.8%), Ubrelvy $1,271 million, Qulipta $1,036 million (+57.3%), Venclexta $2,792 million (+8.1%); Imbruvica fell 14.3% and Botox Cosmetic 4.3%, Juvederm 15.6%.
- Heavy external innovation: acquired IPR&D and milestones of $5,016 million in 2025 (Capstan $1.9 billion, Gilgamesh $906 million, Ichnos Glenmark $700 million, Gubra $350 million, ADARx $335 million); pipeline of approximately 90 programs, approximately 60 in mid- and late-stage development, including obesity as a new growth area.
- January 2026 voluntary agreement with the U.S. government: low Medicaid prices, direct-to-patient offerings and a $100 billion pledge of U.S. R&D and capital investment over the next decade, in exchange for a three-year exemption from tariffs and future price mandates.
- Key risks: patent expiry and biosimilars (Skyrizi and Rinvoq U.S. composition of matter patents expire in 2033; no Rinvoq generic expected before April 2037), IRA price setting (Imbruvica from 2026, Vraylar and Linzess from 2027, Botox from 2028), PBM and payer pressure, tariffs, and $52.6 billion of intangibles plus $35.6 billion of goodwill subject to impairment.
- Capital returns: dividends paid of $11.7 billion in 2025; quarterly dividend raised from $1.64 to $1.73 per share (about 5.5%); Moody's upgraded AbbVie to A2 in February 2026.
- Quarterly Report on Form 10-Q for the second quarter of 2026
- Q2 2026 net revenues of $16,990 million, up 10.2% reported (9.5% at constant currency); first-half revenues $32.0 billion, up 11.2% (9.9% at constant currency).
- First-half operating earnings $10.4 billion, diluted EPS $2.42 and operating cash flow $7.3 billion; Q2 net earnings attributable to AbbVie of $3,613 million versus $938 million a year earlier.
- Immunology engines: Skyrizi $5,505 million in Q2 (+24.4%), Rinvoq $2,525 million (+24.5%); Humira down 35.9% to $756 million.
- Neuroscience growth: Vraylar $1,071 million (+18.9%), Botox Therapeutic $1,042 million (+12.2%), Qulipta $350 million (+30.9%), Vyalev $256 million (from $98 million).
- Weak spots: Imbruvica -29.4% to $532 million, Juvederm -6.0%, Mavyret -21.2%, Creon -14.7%.
- Q2 gross margin 75% of net revenues (72% a year earlier) on lower amortisation of intangibles.
- Definitive agreement (June 2026) to acquire Apogee Therapeutics for $135.11 per share, about $10.9 billion, expected to close in Q3 2026, backed by a $10.0 billion 364-day term loan; RemeGen PD-1/VEGF license ($650 million upfront) booked in Q1.
- New launches and approvals: Decnupaz (BPDCN, FDA May 2026), Venclexta plus acalabrutinib in CLL (FDA February 2026), Rinvoq in vitiligo and alopecia areata (EC July 2026), Boey (EC July 2026, after an FDA Complete Response Letter in April 2026).
- Fourth quarter and full year 2025 earnings conference call (transcript)
- FY2025 adjusted EPS of $10, $0.54 above the initial guidance midpoint; net revenues of $61.2 billion beat initial guidance by more than $2 billion, growth of 8.6% despite nearly $16 billion of U.S. Humira erosion since its loss of exclusivity.
- 2026 guidance: net revenues of approximately $67 billion (growth of 9.5%), adjusted EPS of $14.37 to $14.57 excluding future acquired IPR&D; adjusted operating margin approximately 48.5%; free cash flow of $18.5 billion.
- Skyrizi and Rinvoq: $25.9 billion combined in 2025; 2026 guidance of $21.5 billion and $10.1 billion, above the 2027 long-term target; Michael expects both to grow robustly into the 2030s.
- Long-term ambition: high single-digit revenue growth through 2029, with no significant losses of exclusivity until the next decade.
- Neuroscience as a second engine: 2026 guidance of $12.5 billion; Parkinson's (Vyalev, Duodopa, tavapadon) and migraine franchises each seen above $5 billion peak; Michael speaks of three $5 billion plus franchises in neuroscience.
- Business development: over $8 billion invested in external innovation in two years across more than 30 deals; open to late-stage assets as well as early-stage, in immunology, neuroscience, oncology and obesity.
- Pricing: low single-digit price headwinds expected for Skyrizi and Rinvoq; the U.S. government agreement exempts AbbVie from tariffs and pricing mandates during its term; Botox's Medicare selection was already planned for.
- Aesthetics remains challenged in 2026 (guidance $5 billion); the short-acting toxin trenibotulinumtoxinE is expected to expand the toxin market from 2027.
- Second quarter 2026 earnings conference call (transcript)
- Q2 2026 adjusted EPS of $3.65, $0.06 above guidance midpoint, after a $0.17 hit from acquired IPR&D; revenues of nearly $17 billion, $300 million above expectations, growth of 10.2%.
- Full-year 2026 revenue guidance raised by $300 million to approximately $67.6 billion ($600 million raised since the start of the year); adjusted EPS guidance $13.87 to $14.07, including $0.14 of dilution from the Apogee acquisition.
- Skyrizi $5.5 billion (+24%) with share leadership in more than 30 countries; full-year Skyrizi guidance $21.7 billion; Rinvoq more than $2.5 billion (+23.7%).
- Neuroscience more than $3.2 billion (+approximately 20%); 2026 neuroscience guidance $12.7 billion; Parkinson's and oral CGRP franchises each targeted above $5 billion of peak sales; tavapadon approval expected in Q3.
- Apogee Therapeutics acquisition adds long-acting biologics in atopic dermatitis and respiratory disease; Michael: it will "bolster AbbVie's leading immunology portfolio"; net leverage back to 2 times within 2 to 3 years of closing.
- Rinvoq's vitiligo and alopecia areata indications together expected to approach $2 billion of peak sales.
- Oncology more than $1.6 billion (-2.4%) as Imbruvica fell 29.4% on IRA pricing and competition; aesthetics nearly $1.3 billion (-0.9%).
- Skyrizi regulatory data protection runs to 2031, so biosimilar filings are not expected before the end of the decade; payer concessions remain low single digit.
Questions about AbbVie
What does AbbVie do?
AbbVie discovers, develops and sells medicines and aesthetic products, with leadership positions in immunology (Skyrizi, Rinvoq), neuroscience (Vraylar, Botox Therapeutic), oncology (Venclexta, Imbruvica) and aesthetics (Botox Cosmetic, Juvederm).
What is AbbVie's revenue?
FY2025 net revenues were $61.2 billion, up 8.6%. 2026 guidance was raised to approximately $67.6 billion in July 2026.
How many employees does AbbVie have?
AbbVie employed approximately 57,000 people in over 70 countries at December 31, 2025.
What is AbbVie's growth strategy?
It relies on Skyrizi and Rinvoq growing into the 2030s, neuroscience as a second engine, oncology and aesthetics launches, and business development including obesity, aiming for high single-digit revenue growth through 2029.
Who leads AbbVie?
Robert A. Michael is Chairman and CEO, Scott T. Reents is CFO, Jeffrey R. Stewart is Chief Commercial Officer and Roopal Thakkar leads R&D as Chief Scientific Officer.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)